| Property |
Value |
| Category |
Drug Delivery Technology |
| Target |
Alzheimer's, Parkinson's, ALS, Multiple diseases |
| Mechanism |
Direct nose-to-brain drug delivery via olfactory/trigeminal pathways |
| Status |
Clinical Trials (various phases) |
Intranasal drug delivery represents a revolutionary approach for treating neurodegenerative diseases by bypassing the blood-brain barrier (BBB) and delivering therapeutic agents directly to the brain. This method offers significant advantages over traditional oral and intravenous delivery, including rapid onset, reduced systemic side effects, and improved brain bioavailability.
The nasal cavity provides two main routes for drug delivery to the CNS:
-
Olfactory pathway (direct):
- Drugs diffuse along olfactory nerve fibers
- Transport through olfactory epithelium to olfactory bulb
- Direct entry into brain parenchyma
-
Trigeminal pathway (direct):
- Drugs enter through trigeminal nerve endings
- Distribution to brainstem and limbic structures
- Faster onset for brainstem disorders
| Factor |
Intranasal |
Oral/IV |
| BBB penetration |
Direct |
Limited |
| Onset of action |
Minutes |
Hours |
| Systemic exposure |
Minimal |
High |
| Dosing frequency |
Reduced |
Multiple |
| Patient compliance |
High |
Moderate |
- Intranasal insulin (e.g., detemir, aspart) - improves cognition
- Intranasal curcumin - anti-inflammatory, anti-amyloid
- Intranasal BDNF - neurotrophic support
- Intranasal memantine - NMDA antagonist
- Intranasal GDNF - dopaminergic neuroprotection
- Intranasal ropinirole - dopamine agonist
- Intranasal apomorphine - rescue therapy
- Intranasal glutathione - antioxidant
- Intranasal CNTF - motor neuron protection
- Intranasal VEGF - neurotrophic effects
- Intranasal edaravone - antioxidant
- Intranasal oxytocin - social cognition
- Intranasal orexin - wakefulness
- Intranasal estradiol - neuroprotection
| Trial |
Drug |
Indication |
Outcome |
| Phase II |
Intranasal insulin |
AD/MCI |
Improved cognition |
| Phase I/II |
Intranasal GDNF |
PD |
Safety established |
| Phase I |
Intranasal VEGF |
ALS |
Safety established |
- Intranasal insulin for Alzheimer's (multiple)
- Intranasal leptin for obesity-related cognitive decline
- Intranasal melatonin for sleep disorders in PD
- Particle size - Optimal: 10-100 μm
- Lipophilicity - Higher = better absorption
- Molecular weight - <1000 Da preferred
- pH - 4.5-7.0 for nasal tolerance
- Mucoadhesion - Prolonged contact time
- Nasal sprays (pressurized)
- Nebulizers (vibrating mesh)
- Powder formulations
- Liposomal formulations
- Variable absorption - Individual differences in nasal physiology
- Limited volume - ~100-200 μL per nostril
- Mucociliary clearance - Rapid removal
- Nasal irritation - Chronic use complications
- Olfactory damage - Potential toxicity
- Nanoparticle formulations - Enhanced delivery
- Olfactory targeting - Direct olfactory bulb delivery
- Combination therapies - Multiple agents
- Biomarker integration - Personalized dosing
- Cell-penetrating peptides - Improved transport
The study of Intranasal Therapy For Neurodegeneration has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Dhuria SV, et al. (2010). Intranasal delivery to the central nervous system: mechanisms and experimental considerations. J Pharm Sci. 99(4):1654-1673. PMID:19877171
- Chapman CD, et al. (2013). Intranasal insulin in Alzheimer's disease: food for thought. Neurobiol Aging. 34(12):2917.e1-2917.e6. PMID:23850343
- Craft S, et al. (2012). Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment. Arch Neurol. 69(1):29-38. PMID:21911655
- Hanson LR, et al. (2012). Intranasal delivery of neurotrophic factors BDNF, GDNF, NGF, and VEGF. Methods Mol Biol. 846:305-316. PMID:22367769
- Lochhead JJ, et al. (2015). Intranasal peptide delivery to the brain. Adv Drug Deliv Rev. 90:63-72. PMID:25465132